Adapting tissue-engineered in vitro CNS models for high-throughput study of neurodegeneration
- PMID: 28507726
- PMCID: PMC5415290
- DOI: 10.1177/2041731417697920
Adapting tissue-engineered in vitro CNS models for high-throughput study of neurodegeneration
Abstract
Neurodegenerative conditions remain difficult to treat, with the continuing failure to see therapeutic research successfully advance to clinical trials. One of the obstacles that must be overcome is to develop enhanced models of disease. Tissue engineering techniques enable us to create organised artificial central nervous system tissue that has the potential to improve the drug development process. This study presents a replicable model of neurodegenerative pathology through the use of engineered neural tissue co-cultures that can incorporate cells from various sources and allow degeneration and protection of neurons to be observed easily and measured, following exposure to neurotoxic compounds - okadaic acid and 1-methyl-4-phenylpyridinium. Furthermore, the technology has been miniaturised through development of a mould with 6 mm length that recreates the advantageous features of engineered neural tissue co-cultures at a scale suitable for commercial research and development. Integration of human-derived induced pluripotent stem cells aids more accurate modelling of human diseases, creating new possibilities for engineered neural tissue co-cultures and their use in drug screening.
Keywords: Neurodegeneration; drug screening; induced pluripotent stem cells; neurons; three-dimensional models.
Conflict of interest statement
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Figures
References
-
- Katsuno M, Tanaka F, Sobue G. Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2012; 83(3): 329–335. - PubMed
-
- Stanzione P, Tropepi D. Drugs and clinical trials in neurodegenerative diseases. Ann Ist Super Sanita 2011; 47(1): 49–54. - PubMed
-
- Olanow CW, Brundin P. Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder? Mov Disord 2013; 28(1): 31–40. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
